Reversal of Ventricular Remodeling with Toprol-XL
Study identifier:276
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
-
Medical condition
Heart Failure, Congestive
Phase
Phase 3
Healthy volunteers
No
Study drug
Seloken ZOK/Toprol-XL, Placebo
Sex
All
Actual Enrollment
300
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Aug 2001
Primary Completion Date: 01 Sept 2003
Study Completion Date: 01 Sept 2003
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: None
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2010 by AstraZeneca L.P.
Sponsors
AstraZeneca L.P.
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Contact
AstraZeneca Information Center Telephone: 800-236-9933
